Close
FINDING CURES TOGETHER<sup>SM</sup>

Media Advisories

 

 

New Blog Posts from the American Association for Cancer Research14679257/2/2015 7:17:56 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx34False2015-07-02T16:00:00Z<div class="ExternalClass844E45EA84074CA594A6E5226F30123A"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), celebrated its first anniversary Wednesday, July 1. <a href="http&#58;//blog.aacr.org/cancer-research-catalyst-has-had-quite-a-first-year/" target="_blank">One hundred twenty-five posts later</a>, the <a href="http&#58;//philly.org/content.php?page=2012_Philadelphia_Pepperpot_Awards" target="_blank">award-winning blog </a>has been the perfect vehicle for accelerating the growth and spread of knowledge about cancer, communicating the latest happenings of the AACR, and providing helpful and interesting information to AACR members and the public. </p><p><strong>Posts this week&#58;</strong></p><p>Srivani Ravoori, PhD, AACR’s senior science writer, wrote a two-part series about drug resistance and the enigma of the epidermal growth factor receptor (EGFR). Read <a href="http&#58;//blog.aacr.org/overcoming-drug-resistance-the-egfr-enigma-part-1/" target="_blank">Part 1&#58; Overcoming Resistance to EGFR TKIs</a> and <a href="http&#58;//blog.aacr.org/overcoming-drug-resistance-the-egfr-enigma-part-2/" target="_blank">Part 2&#58; Overcoming Resistance to Anti-EGFR Antibody Therapies</a>. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe.&#160;&#160;</p></div>
Senate Labor-HHS-Education Appropriations Bill Proposes Largest Annual Increase for NIH Since 200382646/26/2015 2:13:21 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx33False2015-06-26T13:00:00ZAACR Commends Investment in Medical Research; Experts Available for Interviews<div class="ExternalClassC751054B33FD41B7A13B07A998B9AAC0"><p>WASHINGTON, D.C. — The American Association for Cancer Research (AACR) commends both the House and the Senate Appropriations Committees for making medical research a priority, and for recognizing the critical role that National Institutes of Health (NIH)-funded research plays in saving lives for those with cancer and other diseases. This funding is urgently needed if we are to continue to uncover scientific breakthroughs.</p><p>AACR President José Baselga, MD, PhD, is available for interviews. He is the physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center and is an internationally recognized physician and scientist who focuses on developing targeted therapies for breast cancer.</p><p>&quot;With advances in technology, there has never been a more exciting time in biomedical research against cancer and other diseases,&quot; Baselga said. &quot;While the NIH budget has stagnated for more than a decade, the Senate's proposal of a $2 billion increase in NIH funding for the Fiscal Year [FY] 2016 budget is a positive paradigm shift that reflects the importance of biomedical research, and overcomes the previous hurdles that have resulted from budget sequestration. This additional funding has the potential to open up new opportunities to cultivate junior scientists, to advance our understanding of genetics, and ultimately, to develop more effective treatments for patients with cancer and other diseases.&quot;</p><p>Jon Retzlaff, managing director of the AACR's Office of Science Policy and Government Affairs is also available for interviews to discuss the AACR's position, the political landscape, and future considerations that would enable this bill to be passed by the Senate.</p><p>&quot;This increase of approximately $2 billion is a significant step toward putting the NIH back on a path of sustained, predictable growth,&quot; said Retzlaff. &quot;The AACR applauds this bipartisan support for medical research, as well as specifically, Chairman Blunt's leadership and commitment to supporting the NIH.</p><p>&quot;However, we also recognize that this proposed increase for NIH is likely going to be dependent on a broader budget agreement to ease these restrictive spending caps that are in place for FY 2016, especially since Senate Democrats are threatening to filibuster all spending bills that adhere to the sequester budget caps, and the president has promised to veto any of the spending bills that arrive at his desk adhering to the budget caps. Therefore, this situation underscores the enormous importance for Democrats and Republicans to come together to ensure that the necessary additional resources are provided for both defense and nondefense discretionary programs.&quot;</p><p>Yesterday, the Senate Appropriations Committee approved the Labor, Health, and Human Services, and Education FY 2016 spending bill, which provides a $2 billion increase, 6.6 percent, in funding for the NIH— the largest increase since 2003. In addition, the committee recommended a 5 percent increase of $250 million in funding for the National Cancer Institute. These increases exceed those approved by the House Appropriations Committee June 24.</p><p>The markup of the Senate appropriations bill dovetails with the national discussion underway regarding the president's Precision Medicine Initiative, which received a $200 million funding commitment in the proposed bill. Baselga and other fellows of the AACR Academy participated in a Congressional briefing on precision medicine in partnership with the White House Office of Science and Technology June 17 to share their expertise and insight into how to best advance medical research, and emphasized the importance of investing in and harnessing the latest genomics technologies available to prevent or effectively treat cancer and many other diseases.</p></div>
Cancer Research Catalyst Blog: Powerhouse Cancer Experts Converge on Capitol Hill to Discuss Precision Medicine82636/19/2015 1:54:44 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx32False2015-06-17T19:00:00Z<div class="ExternalClass0A64A2C3C95042CC906408378B2EEDBB"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features a <a href="http&#58;//blog.aacr.org/fellows-of-the-aacr-academy-special-briefing-precision-medicine/" target="_blank">post about a congressional briefing held today</a> to stimulate additional support for President Obama’s Precision Medicine Initiative and to address the importance of biomedical funding. </p><p>The AACR held the special briefing, titled “<a href="/AdvocacyPolicy/GovernmentAffairs/Pages/fellows-of-the-AACR-academy.aspx">Saving Lives in the New Era of Precision Medicine</a>,” in conjunction with its fellows of the AACR Academy, Rep. André Carson, D-Ind., and Rep. David McKinley, R-W.Va.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
AACR to Sponsor Congressional Briefing June 17 to Discuss the Latest in Cancer Research and Precision Medicine82626/15/2015 3:52:13 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx31False2015-06-15T15:45:00ZBriefing will include participation from the White House to highlight President Obama's Precision Medicine Initiative<div class="ExternalClass2271498C1ED142F580451536DA7A1CA3"><p>WASHINGTON — The American Association for Cancer Research (AACR), in conjunction with its fellows of the AACR Academy and in cooperation with Rep. David McKinley, R-W.Va., and Rep. André Carson, D-Ind., will hold a special briefing titled “<a href="/AdvocacyPolicy/GovernmentAffairs/Pages/fellows-of-the-AACR-academy.aspx">Saving Lives in the New Era of Precision Medicine</a>,” Wednesday, June 17, noon – 1&#58;30 p.m., in room B-340 of the Rayburn House Office Building on Capitol Hill.</p><p>This briefing will feature expert discussion regarding the promise surrounding President Barack Obama’s Precision Medicine Initiative and will stress the importance of providing robust and sustained increases in funding for the National Institutes of Health (NIH) and the National Cancer Institute.</p><p>Jo Handelsman, PhD, associate director for science, White House Office of Science and Technology Policy, will explain how the potential for precision medicine to improve care and produce new treatments has only begun to be harnessed. Handelsman is also the president’s scientific adviser for the Precision Medicine Initiative.</p><p>José Baselga, MD, PhD, AACR president; Carlos L. Arteaga, MD, AACR immediate past-president; Elizabeth H. Blackburn, PhD, AACR past-president and 2009 Nobel Prize in physiology or medicine recipient; and other experts will discuss the vital importance of cancer research and biomedical science to the economic health and well-being of our nation. Speakers will also describe how innovation in precision medicine has the ability to markedly reduce the human and economic costs of cancer.</p><p>The AACR especially thanks Reps. McKinley and Carson for their support of this event. Together they have championed funding for the NIH by spearheading a bipartisan letter to House appropriators requesting $32 billion for the NIH in fiscal year 2016.</p></div>
Cancer Research Catalyst Blog: Q&A With Dr. Elaine Mardis on Precision Medicine82616/15/2015 2:55:40 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx30False2015-06-15T14:55:00Z<div class="ExternalClass11AA0DD6CA434130BB27A72DF88F7734"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features an <a href="http&#58;//blog.aacr.org/qa-elaine-r-mardis-phd-integrating-clinical-genomics-cancer-therapy/" target="_blank">interview with Elaine Mardis, PhD</a>, director of the McDonnell Genome Institute at Washington University School of Medicine in St. Louis, and co-chair of the AACR’s third conference in its Precision Medicine Series, “<a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=42">Integrating Clinical Genomics and Cancer Therapy</a>,” which is currently being held in Salt Lake City. </p><p>Mardis provided insight into the transformative studies being presented at the meeting, and offered her expert opinion on the effect of precision medicine in the near and distant future of cancer treatments.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Cancer Research Catalyst Blog: Looking at the New AACR Radiation Science Working Group and Better Ways to Determine Treatment Options for Prostate Cancer82596/9/2015 4:09:20 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx29False2015-06-09T16:00:00Z<div class="ExternalClassDCD46FBAF8E441E590E61120E774E002"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features an <a href="http&#58;//blog.aacr.org/qa-theodore-lawrence-md-phd-radiation-science-and-medicine-working-group/" target="_blank">interview with Theodore Lawrence, MD, PhD</a>, director of the University of Michigan Comprehensive Cancer Center, about the unique roles that the new the AACR Radiation Science and Medicine Working Group will have in advancing radiation-related cancer research and therapies.</p><p>In addition, Carlos Moreno, PhD, associate professor in the Departments of Pathology and Laboratory Medicine and Biomedical Informatics at the Emory University School of Medicine and member of the Cancer Genetics and Epigenetics Program at Winship Cancer Institute, provides a guest post, titled <a href="http&#58;//blog.aacr.org/new-tests-to-improve-decision-making-in-prostate-cancer-treatment/" target="_blank">New Tests to Improve Decision Making in Prostate Cancer Treatment</a>. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Cancer Research Catalyst Blog: Clinical Trials and Scientist↔Survivor Program Highlights From AACR Annual Meeting 201582585/19/2015 3:53:29 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx28False2015-05-19T15:45:00Z<div class="ExternalClassA5495D54A4304693B5BF9E19704E209B"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features a post from Srivani Ravoori, PhD, senior science writer at the AACR, titled <a href="http&#58;//blog.aacr.org/clinical-trials-highlighted-at-aacr-annual-meeting-2015/" target="_blank">Clinical Trials Highlighted at the AACR Annual Meeting 2015</a>. For this post, Ravoori spoke with Johann de Bono, MBBS, PhD, co-chair of the Annual Meeting Clinical Trials Committee, about this year’s successful clinical trials program, which showcased promising advances in immunotherapy and targeted therapy combinations.</p><p>In addition, Leigh Labrie, associate editor of <em><a href="http&#58;//www.cancertodaymag.org/" target="_blank">Cancer Today</a> </em>magazine, highlights the AACR’s Scientist↔Survivor Program, which is now in its 17th year, in a post titled <a href="http&#58;//blog.aacr.org/aacr-scientist-survivor-program-facilitates-open-dialogue-between-patient-advocates-and-scientists/" target="_blank">AACR Scientist↔Survivor Program Facilitates Open Dialogue Between Patient Advocates and Scientists</a>. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
AACR to Sponsor Congressional Briefing May 14 to Discuss Issues Surrounding Electronic Cigarettes82575/13/2015 2:54:48 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx27False2015-05-12T16:00:00Z<div class="ExternalClass6530166469C648EE8D011F0769FF3291"><p>​WASHINGTON, D.C. — The American Association for Cancer Research (AACR), in conjunction with Rep. Jackie Speier (D-Calif.) and Sen. Richard Blumenthal (D-Conn.), will host a briefing titled, “Electronic Cigarettes&#58; What You Don’t Know Can Hurt You,” Thursday, May 14, noon – 1 p.m., in Room H-137 of the U.S. Capitol.&#160; </p><p>The briefing will feature remarks from Speier and Blumenthal, as well as Roy S. Herbst, MD, PhD, chief of medical oncology, Yale Comprehensive Cancer Center, New Haven, Connecticut, and chair of the AACR Tobacco and Cancer Subcommittee; Maciej Goniewicz, PhD, PharmD, assistant professor of oncology, Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, New York; and Brian King, PhD, MPH, acting deputy director for research translation, Office on Smoking and Health, Centers for Disease Control and Prevention, Atlanta.</p><p>The increase in the use of electronic cigarettes and other electronic nicotine delivery systems (ENDS) has raised complex regulatory issues and public health concerns, and this briefing will educate attendees on the types of ENDS that are available, what we currently know about them, and what we still need to learn to best protect public health. The speakers will also discuss a <a href="http&#58;//clincancerres.aacrjournals.org/content/early/2015/01/04/1078-0432.CCR-14-2544.full.pdf+html" target="_blank">joint policy statement </a>released in January 2015 by the AACR and the American Society of Clinical Oncology titled, Electronic Nicotine Delivery Systems&#58; A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology.</p><p><a href="/ADVOCACYPOLICY/GOVERNMENTAFFAIRS/PAGES/RECOMMENDATIONS-FOR-THE-REGULATION-OF-ELECTRONIC-CIGARETTES.ASPX">Learn more</a> about electronic cigarettes and other ENDS.</p><p>For more information, contact Carl Wonders at <a href="mailto&#58;carl.wonders@aacr.org">carl.wonders@aacr.org</a> or 267-765-1027.</p></div>
Scientists From the AACR Annual Meeting to Participate in ABC News' April 21 Twitter Chat, Breakthroughs in Cancer Research82564/16/2015 9:07:49 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx26False2015-04-16T21:00:00Z<div class="ExternalClass1F107CDD856043D983A8AFB3902F889B"><p>The American Association for Cancer Research (AACR) President Carlos L. Arteaga, MD, PhD; President-elect José Baselga, MD, PhD; and Annual Meeting Program Chair Lewis C. Cantley, PhD, will be tweeting live during the ABC News Twitter chat Tuesday, April 21, 1-2 p.m. ET, on the latest advances in cancer research. The Twitter chat will be moderated by ABC News Medical Editor Richard Besser, MD, and will also be streamed live on <a href="https&#58;//itunes.apple.com/app/id972909677" target="_blank">Periscope</a>, an iOS app that enables users to broadcast live video.&#160; </p><p>Arteaga is president of the AACR and director of the Breast Cancer Program, director of the Vanderbilt-Ingram Cancer Center Research Network, director of the Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center, and a professor of medicine and cancer biology at Vanderbilt University School of Medicine; Baselga is president-elect of the AACR and physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center; and Cantley is program chair of the AACR Annual Meeting 2015 and the Meyer Director of the Sandra and Edward Meyer Cancer Center, the Margaret and Herman Sokol professor in oncology research, and a professor of cancer biology medicine at Weill Cornell Medical College. </p><p>They will join a panel of other AACR members at the AACR Annual Meeting 2015, where the latest and most exciting basic, translational, and clinical discoveries in cancer research are presented to more than 18,500 attendees.&#160;&#160; </p><p>Follow the conversation on Twitter and join in&#58; <a href="https&#58;//twitter.com/search?q=%23abcDrBchat" target="_blank">#abcDrBchat</a>. </p><p>Follow the AACR on Twitter&#58; <a href="http&#58;//www.twitter.com/aacr" target="_blank">@AACR</a>.<br><a href="https&#58;//itunes.apple.com/app/id972909677" target="_blank">Download the Periscope app</a> and follow the AACR&#58; @AACR.</p></div>
Cancer Research Catalyst Blog: FDA Approves First Immunotherapy for Children With Cancer; Increasing Clinical Trial Participation82553/26/2015 9:05:11 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx25False2015-03-26T16:00:00Z<div class="ExternalClass1CBB8CDC42B440868B083B9DD2AFA40A"><p>​<em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features a post from Srivani Ravoori, PhD, senior science writer at the AACR, titled <a href="http&#58;//blog.aacr.org/fda-approval-dinutuximab/" target="_blank">FDA Approves First Immunotherapy for Children With Cancer</a>.</p><p>In addition, Toni Kay Mangskau, clinical trials referral coordinator at the Mayo Clinic Cancer Center, weighs in on methods to help patients access clinical trials more easily and improve trial participation in her guest post, titled <a href="http&#58;//blog.aacr.org/a-simple-act-increasing-clinical-trial-participation/" target="_blank">A Simple Act&#58; Increasing Clinical Trial Participation</a>.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>